EspeRare Fondation

Ultimate Medicine AG, a Swiss preclinical pharmaceutical company, is developing an innovative oral treatment for age-related cognitive disorders. Our approach targets an overlooked pathway complementing standard amyloid-β/tau therapies.

The Future Rewritten: Unlocking Genome Editing. By fusing directed evolution, high-throughput characterization, and AI, Nerai creates novel CRISPR editors, more precise and more powerful, making gene editing safer and accessible to more patients.

At OBaris, we are revolutionizing peptide drug delivery with OctoPatch®—a painless, patient-friendly platform designed to replace injections. Our innovative technology enables pharma partners to target various diseases, improving patient compliance and treatment outcomes.